Holloway Michael Andrew 4

What Happened Michael Andrew Holloway, a director of Lixte Biotechnology Holdings, Inc. (LIXT), had 25,000 stock options canceled and received 25,000 restricted stock units (RSUs) in exchange on April 15, 2026. The filing shows the RSU grant (code A) and a disposition to the issuer for the canceled options (code D—derivative). No dollar prices are reported (N/A). The 25,000 RSUs vest immediately upon grant.

Key Details

• Transaction date: April 15, 2026. Form 4 filed April 17, 2026 (timely filing).
• Grant: 25,000 RSUs (each RSU = contingent right to 1 share upon vesting).
• Disposition: 25,000 options canceled (derivative disposition to issuer).
• Price/Value: N/A in the filing.
• Shares owned after transaction: not specified in this Form 4.
• Footnotes: The options were canceled under a Stock Option Cancellation Agreement dated April 15, 2026; in exchange Holloway received 25,000 RSUs under the company’s 2020 Stock Incentive Plan and the April 15, 2026 award agreement. The RSUs vest immediately. The canceled options originally had a multi‑date vesting schedule (50% on grant date; remaining 50% vesting in installments).
• Timeliness: Filing appears timely (within the standard two business days).

Context This was an award/derivative exchange (options canceled for RSUs), not an open‑market purchase or sale. Because the RSUs vest immediately, Holloway now has a vested right to receive up to 25,000 shares (subject to settlement terms); the filing does not state cash value or whether the RSUs have been settled into shares. Such exchanges are typically administrative/compensation-related and do not by themselves indicate a buy or sell signal.